MedTrace Logo

Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).

NCT07401498 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-02-10

No results posted yet for this study

Summary

Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited.

Objective: To assess trends and characteristics of projects directly related to Lymph Node Dissection and to identify independent risk factors for their development.

Conditions

  • Lymph Node Dissection
  • Advanced Non-small Cell Lung Cancer (NSCLC)

Interventions

PROCEDURE

Systematic mediastinal nodal dissection (SND)

removal of all tissue with lymph nodes in the relevant areas with a minimum of: ≥3 mediastinal stations always including group 7 lymph nodes.

PROCEDURE

Lobe-Specific Lymph Node Dissection (L-SND)

removal of all tissue with lymph nodes in the relevant areas with a minimum of: ≥3 mediastinal stations always including group 7 lymph nodes.

Sponsors & Collaborators

  • National Medical Research Center of Phthisiopulmonology and Infectious Diseases

    collaborator OTHER_GOV

  • National Medical Research Radiological Centre of the Ministry of Health of Russia

    collaborator OTHER

  • Regional Clinical Oncology Dispensary

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-14
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07401498 on ClinicalTrials.gov